Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cuba to upgrade homegrown COVID-19 vaccine to confront Omicron

12/01/2021 | 12:50pm EST

HAVANA, Dec 1 (Reuters) - Cuban health authorities said that researchers in the communist-run country are upgrading its homegrown COVID vaccines to ensure protection against the new Omicron variant.

The Caribbean island nation, whose economy hinges on tourism, sharply eased entry requirements in mid-November following a successful inoculation drive with domestically developed vaccines. Both infections and deaths from COVID-19 https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/cuba have dropped off to 2% or less of their peaks, according to a Reuters tally.

Vicente Verez, director of Cuba's Finlay Institute for Vaccines, said on Tuesday on state-run media it was clear that Cuba's Soberana vaccine would continue to provide "a certain level of protection" against Omicron, but said the extent of that protection was still uncertain.

“We decided as of last week to start developing a Soberana Plus variant having the Omicron RBD protein," Verez said, referring to the receptor-binding domain (RBD), a key part of the virus located on its "spike". "We have already started it, and that protein is being built at the moment."

Some global vaccine manufacturers, including BioNTech https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-ceo-says-current-vaccine-likely-protect-against-severe-covid-omicron-2021-11-30 , have expressed guarded confidence that their vaccines would offer strong protection against Omicron. Others, like Moderna, have raised the prospect of a material drop in protection.

It is not yet clear whether Omicron is more transmissible than other variants, or if it causes more severe disease.

Cuba has developed an unusually large biotech sector for a country its size, partly in a bid for sovereignty given crippling U.S. sanctions. It has made vaccines available to several of its allies, including Venezuela, Nicaragua and Iran.

Cuba has yet to detect the Omicron variant, but earlier this week announced it would tighten restrictions beginning Dec. 4 on passengers from certain African countries https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-tightens-restrictions-eight-african-countries-over-omicron-concerns-2021-11-29 due to the new variant.

(Reporting by Reuters TV; writing by Dave Sherwood; Editing by Lisa Shumaker)


ę Reuters 2021
All news about MODERNA, INC.
01:29pChile to purchase 2 million Moderna COVID-19 vaccine doses
RE
08:25aLEIDEN UNIVERSITY : mRNA boosters are the most effective upon receiving Janssen vaccinatio..
AQ
06:50aINSIDER SELL : Moderna
MT
05:53aNORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
01/21Moderna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
01/21Boosters provide 'added protection' against Omicron -CDC
RE
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
RE
01/21Booster shots needed against omicron, CDC studies show
AQ
01/21U.S. studies highlight the need for COVID boosters to fight Omicron
RE
01/21CDC : Vaccines less effective against Omicron, but still reduce risk for serious illness
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 644 M - -
Net income 2021 11 173 M - -
Net cash 2021 10 558 M - -
P/E ratio 2021 6,02x
Yield 2021 -
Capitalization 64 900 M 64 900 M -
EV / Sales 2021 3,08x
EV / Sales 2022 2,03x
Nbr of Employees 1 300
Free-Float -
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 160,07 $
Average target price 266,88 $
Spread / Average Target 66,7%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508
CELLTRION, INC.-15.91%19 126